NF-κB Signaling in Bone Metabolism and Differentiation

NF-κB (nuclear factor-κB) signalling occupies a central role in skeletal homeostasis by orchestrating the balance between bone formation and resorption. In the canonical pathway, inflammatory cytokines such as tumour necrosis factor-α (TNF-α) and interleukin-1β trigger the activation of IκB kinase (IKK), resulting in the release and nuclear translocation of p65/p50 dimers that induce osteoclastogenic genes. The alternative pathway, activated by receptor activator of NF-κB ligand (RANKL) and CD40 ligand, relies on NF-κB inducing kinase (NIK) to process p100 into p52, promoting osteoclast differentiation. Beyond osteoclasts, NF-κB signalling also modulates osteoblast lineage commitment, inhibiting bone-forming programmes under inflammatory conditions. Genetic disruptions of key components—for example, double-knockouts of NF-κB1/2 or mutations in the IKKγ-encoding gene—result in dramatic skeletal phenotypes from osteopetrosis to high-mass bone. Recent advances have uncovered molecular regulators that fine-tune NF-κB activity in mesenchymal precursors, osteocytes and chondrocytes, revealing opportunities for targeted therapies. Uncoupling agents, peptide inhibitors and small molecules designed to selectively block canonical or alternative signalling have demonstrated efficacy in preclinical models of osteoporosis, osteoarthritis and periodontitis. These insights underscore NF-κB as both a master regulator of bone cell fate and a promising therapeutic target for a spectrum of bone disorders.

Research from Nature Portfolio

No recent Nature Portfolio content available.

NF-κB Signaling in Bone Metabolism and Differentiation publication trend

The graph below shows the total number of articles in nf-κb signaling in bone metabolism and differentiation across all publications each year (not limited to Nature Index journals).

Technical terms

NF-κB: A family of transcription factors central to immune responses and bone cell regulation.

Canonical pathway: NF-κB activation route involving IKK-mediated IκB degradation and p65/p50 nuclear translocation.

Alternative pathway: A distinct NF-κB route dependent on NIK-mediated p100 processing to p52/RelB dimers.

Osteoclast: A multinucleated cell responsible for bone resorption, driven by RANKL-induced NF-κB signals.

Osteoblast: A bone-forming cell whose differentiation can be inhibited by NF-κB under inflammatory conditions.

RANKL: Receptor activator of NF-κB ligand, a key cytokine that initiates osteoclastogenesis via both pathways.

IκB: An inhibitory protein that sequesters NF-κB in the cytoplasm until phosphorylated and degraded by IKK.

References

1. IĸB Protein BCL3 as a Controller of Osteogenesis and Bone Health. Arthritis & Rheumatology (2023).
2. Anti–NF-κB peptide derived from nuclear acidic protein attenuates ovariectomy-induced osteoporosis in mice. JCI Insight (2023).
3. Inhibition of non-canonical NF-κB signaling suppresses periodontal inflammation and bone loss. Frontiers in Immunology (2023).
4. The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition “Killing Two Birds with One Stone”?. Cells (2019).
5. Critical Roles of NF-κB Signaling Molecules in Bone Metabolism Revealed by Genetic Mutations in Osteopetrosis. International Journal of Molecular Sciences (2022).